Compassion Therapy Services Llc Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 4043 Violet Ave, Saint Clair, MI 48079 Phone: 810-300-6614 |
Eastwood Clinics Counselor Medicare: Not Enrolled in Medicare Practice Location: 132 Trumbull St, Saint Clair, MI 48079 Phone: 810-329-5340 Fax: 810-329-8964 |
Eastwood Clinics Counselor Medicare: Not Enrolled in Medicare Practice Location: 132 Trumbull St, Saint Clair, MI 48079 Phone: 810-329-5340 Fax: 810-329-8964 |
Monica Alderman, Counseling And Supervision Services, Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 4383 Irene Dr, Saint Clair, MI 48079 Phone: 586-453-2945 |
Pegasus Therapy Llc Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 635 Saint Andrews, Saint Clair, MI 48079 Phone: 810-650-2732 |
Beacon Of Hope Counseling Llc Social Worker - Clinical Medicare: Medicare Enrolled Practice Location: 1645 Goffe St, Saint Clair, MI 48079 Phone: 810-289-2720 Fax: 810-857-6606 |
News Archive
Royal Philips (NYSE: PHG AEX: PHIA) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its precision planning application for Transcatheter Aortic-Valve Implantation (TAVI) treatments.
A group of scientists at the Instituto Gulbenkian de Ci-ncia, in Portugal, have uncovered a surprising link between the cell's skeleton and organ size. The team, led by Florence Janody, show in the journal Development, that one of the proteins that regulates the skeleton of the cell also acts to blocks activation of genes that promote cell survival and proliferation.
Scientists at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal have discovered a key mechanism used by cells to efficiently distribute chromosomes to new cells during cell multiplication.
Two studies led by the Mental Health Unit of the Virgen del Rocio University Hospital and involving researchers from the US conclude that antipsychotic drugs could have a protective effect against SARS-CoV-2. For this reason, patients treated with these drugs have a lower risk of becoming infected or suffer a milder form of the disease if they do become infected.
Transcept Pharmaceuticals, Inc. today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). As previously announced, the Complete Response Letter, received by Transcept on October 28, 2009, indicated that the FDA could not approve the NDA in its present form.
› Verified 1 days ago